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ABSTRACT
Background: Patient-reported outcomes (PROs) are the consequences of
disease and/or its treatment as reported by the patient. The importance of
PRO measures in clinical trials for new drugs, biological agents, and
devices was underscored by the release of the US Food and Drug Admin-
istration’s draft guidance for industry titled “Patient-Reported Outcome
Measures: Use in Medical Product Development to Support Labeling
Claims.” The intent of the guidance was to describe how the FDA will
evaluate the appropriateness and adequacy of PRO measures used as
effectiveness end points in clinical trials. In response to the expressed need
of ISPOR members for further clariﬁcation of several aspects of the draft
guidance, ISPOR’s Health Science Policy Council created three task forces,
one of which was charged with addressing the implications of the draft
guidance for the collection of PRO data using electronic data capture
modes of administration (ePRO). The objective of this report is to present
recommendations from ISPOR’s ePRO Good Research Practices Task
Force regarding the evidence necessary to support the comparability, or
measurement equivalence, of ePROs to the paper-based PRO measures
from which they were adapted.
Methods: The task force was composed of the leadership team of ISPOR’s
ePRO Working Group and members of another group (i.e., ePRO Con-
sensus Development Working Group) that had already begun to develop
recommendations regarding ePRO good research practices. The resulting
task force membership reﬂected a broad array of backgrounds, perspec-
tives, and expertise that enriched the development of this report. The prior
work became the starting point for the Task Force report. A subset of the
task force members became the writing team that prepared subsequent
iterations of the report that were distributed to the full task force for
review and feedback. In addition, review beyond the task force was sought
and obtained. Along with a presentation and discussion period at an
ISPOR meeting, a draft version of the full report was distributed to
roughly 220 members of a reviewer group. The reviewer group comprised
individuals who had responded to an emailed invitation to the full mem-
bership of ISPOR. This Task Force report reﬂects the extensive internal
and external input received during the 16-month good research practices
development process.
Results/Recommendations: An ePRO questionnaire that has been
adapted from a paper-based questionnaire ought to produce data that are
equivalent or superior (e.g., higher reliability) to the data produced from
the original paper version. Measurement equivalence is a function of the
comparability of the psychometric properties of the data obtained via the
original and adapted administration mode. This comparability is driven by
the amount of modiﬁcation to the content and format of the original paper
PRO questionnaire required during the migration process. The magnitude
of a particular modiﬁcation is deﬁned with reference to its potential effect
on the content, meaning, or interpretation of the measure’s items and/or
scales. Based on the magnitude of the modiﬁcation, evidence for measure-
ment equivalence can be generated through combinations of the following:
cognitive debrieﬁng/testing, usability testing, equivalence testing, or, if
substantial modiﬁcations have been made, full psychometric testing. As
long as only minor modiﬁcations were made to the measure during the
migration process, a substantial body of existing evidence suggests that
the psychometric properties of the original measure will still hold for the
ePRO version. Hence, an evaluation limited to cognitive debrieﬁng and
usability testing only may be sufﬁcient. However, where more substantive
changes in the migration process has occurred, conﬁrming that the adap-
tation to the ePRO format did not introduce signiﬁcant response bias and
that the two modes of administration produce essentially equivalent
results is necessary. Recommendations regarding the study designs and
statistical approaches for assessing measurement equivalence are provided.
Conclusions: The electronic administration of PRO measures offers many
advantages over paper administration. We provide a general framework
for decisions regarding the level of evidence needed to support modiﬁca-
tions that are made to PRO measures when they are migrated from paper
to ePRO devices. The key issues include: 1) the determination of the extent
of modiﬁcation required to administer the PRO on the ePRO device and 2)
the selection and implementation of an effective strategy for testing
the measurement equivalence of the two modes of administration. We
hope that these good research practice recommendations provide a path
forward for researchers interested in migrating PRO measures to elec-
tronic data collection platforms.
Keywords: effectiveness, evaluation studies, health-related quality of life,
patient-reported outcomes.
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Introduction
Overview
Patient-reported outcomes (PROs) are the consequences of
disease and/or its treatment as reported by the patient, including
perceptions of health, well-being, symptom experience, function-
ing, and treatment satisfaction. PROs are increasingly being used
to complement safety data, survival rates, and other traditional
indicators of clinical efﬁcacy in therapeutic intervention trials [1].
They enrich the evaluation of treatment effectiveness by provid-
ing the patient perspective. In some cases, such as pain assess-
ment or fatigue, a PRO may be the only viable end point because
there are no observable or measurable physical or physiological
markers of disease or treatment activity [2–4]. In other cases,
where PROs are not the only available end point, they may still
be among the most important.
A number of reports and consensus papers addressing the use
of PROs in clinical research and labeling claims have been pub-
lished during the past several years [5–11]. Regulatory agencies
are being asked increasingly to review and approve protocols
that include PRO measures [12,13]. As of 1994, the majority of
Phase II-IV clinical trials collected some type of PRO data [14].
Willke et al. [12] reviewed the effectiveness end points reported
in FDA-approved product labeling for new molecular entities
approved from 1997 through 2002 and found that PRO end
points were included in 30% (64) of the 215 product labels
examined. For 23 products, PROs were the only end points
reported.
Concurrent with the increased use and signiﬁcance of PROs
in clinical trials has been the steady growth in electronic data
capture (EDC) in clinical trials. There have been missteps along
the way, most notably the perceived lack of adequate technical
support for clinical investigators [15–17]. Adaptation of case
report forms to electronic formats, including electronic modes of
PRO administration (ePROs), must ensure the data collected via
the different methods are equivalent or account for any identiﬁed
differences.
The importance of PRO measures in clinical trials for new
drugs, biological agents, and devices was underscored by the
release of the US Food and Drug Administration’s draft guidance
for industry, “Patient-Reported Outcome Measures: Use in
Medical Product Development to Support Labeling Claims”
[18]. The intent of the guidance was to describe how the FDA
will evaluate the appropriateness and adequacy of PRO measures
used as effectiveness end points in clinical trials. The FDA guid-
ance was created to make the process of developing and review-
ing PRO measures more efﬁcient and transparent for both the
FDA and clinical trial sponsors by outlining basic evaluation
standards. A series of articles commenting on various aspects of
PRO development, selection, testing, analysis, and interpretation
contained in the FDA guidance document were recently pub-
lished [19–25]. Nevertheless, this process continues to evolve and
remains challenging due, in part, to the myriad of possible PRO
measures, the need for various language and cultural adapta-
tions, and the multiple existing and emerging modes of admin-
istration. Furthermore, the draft guidance raised speciﬁc issues
associated with ensuring the comparability of electronic and
paper-based PRO measures [18].
Many PRO measures were originally developed for paper-
and-pencil administration, but may be able to be adapted to
ePRO formats. EDC adaptation of existing PRO measures may
lead to less administrative burden, high patient acceptance,
avoidance of secondary data entry errors, easier implementation
of skip patterns, and more accurate and complete data [26–31].
The FDA has indicated openness to considering the advances
promised by the use of ePRO measures in clinical trials [25].
However, the ePRO measure will be subject to the same scrutiny
as would a paper-based measure. Empirical evidence will be
required to demonstrate that the measurement properties of the
ePRO application are comparable if not superior to the original
PRO format. Needless to say, it would be unwise to consider
moving a paper-based PRO measure to an electronic format for
use in a clinical trial if the original measure does not meet the
standards of the FDA guidance. In addition, migration of existing
PRO measures to ePRO devices should be planned, conducted,
and evaluated with permission and in cooperation with the mea-
sure’s developer whenever possible.
The purpose of this manuscript is to present recommenda-
tions for the evidence necessary to support the comparability or
measurement equivalence of ePROs to the paper-based PRO
measure from which they were adapted. Although a brief review
is provided, this manuscript is not intended to comprehensively
compare and contrast the various modes of ePRO administra-
tion. Furthermore, these recommendations are predicated on the
assumption that for use in clinical trials, the ePRO data collec-
tion and storage infrastructure complies with regulatory require-
ments for sponsor and investigator record keeping, maintenance,
and access. We will not discuss this issue in detail. Record
keeping requirements (addressed in 21 CFR 312.50, 312.58,
312.52, 312.68, 812.140, and 812.145) include the preparation
and maintenance of case histories, record retention, and provi-
sion for the FDA to access, copy, and verify records [32]. In
addition, collection of ePRO data must be compliant with the
Guidance for Industry: E6 Good Clinical Practice (Section 5.5.3)
[33], Guidance for Industry: Computerized Systems Used in
Clinical Investigations [34], and 21 CFR Part 11 [35–37]. Hence,
records must be maintained or submitted in accordance with the
underlying requirements set forth in the Federal Food, Drug, and
Cosmetic Act, the Public Health Service Act, and applicable FDA
regulations (other than part 11).
Task Force Process
After release of the draft PRO guidance in February 2006, the
FDA solicited comments and suggestions to inform the ﬁnaliza-
tion of the guidance. ISPOR membership provided comments to
the FDA identifying the need for clarity on several speciﬁc issues,
including the FDA’s expectations regarding the use of existing
PRO instruments and their modiﬁcations, translating and/or
adapting PRO measures from one language/culture to another,
and changing the mode of administration of PRO measures,
speciﬁcally to electronic data capture (ePRO).
Based on January 2007 recommendations from ISPOR’s
Health Science Policy Council, the ISPOR Board of Directors in
March 2007 approved the formation of three PRO Task Forces
to address the above issues. The task force that came to be
called the ePRO Task Force initially was composed of the lead-
ership team of ISPOR’s ePRO Working Group, which was
chaired by Stephen Joel Coons. Another group already in exist-
ence and also chaired by Prof. Coons, the ePRO Consensus
Development Working Group, was merged into the ePRO Task
Force soon afterward. The resulting task force membership
reﬂected a broad array of backgrounds, perspectives, and
expertise that enriched this good research practices develop-
ment process.
The work that had been begun by the ePRO Consensus
Development Working Group became the starting point for the
ePRO Task Force report. A subset of the task force members
became the writing team that prepared subsequent iterations of
the report. Monthly task force teleconferences were held to
420 Coons et al.
review the progress and provide feedback to the writing team. In
addition, review beyond the task force members was sought and
obtained. An outline of the initial recommendations and future
direction of the ePRO Task Force report was presented as part of
a PRO Forum at the May 2007 ISPOR 12th Annual Interna-
tional Meeting. Questions and feedback from the PRO Forum
participants informed and further deﬁned the content of the Task
Force report. Once a draft version of the full report was com-
pleted, it was distributed in November 2007 to a roughly 220
member reviewer group. The reviewer group comprised individu-
als who had responded afﬁrmatively to an emailed invitation
to the full membership of ISPOR to join the ePRO Working
Group. A considerable amount of substantive feedback was
received from the reviewer group. Based on both the internal and
external input, innumerable iterations of the report were distrib-
uted to the task force members over a 16-month period. This
ﬁnal report reﬂects the culmination of that extensive process.
Types of ePRO Data Collection Devices/Systems
There are two main categories of ePRO administration plat-
forms: voice/auditory devices and screen text devices. Voice/
auditory devices are primarily telephone-based and are com-
monly referred to as interactive voice response (IVR). Screen text
devices provide the respondent with a computerized version
of the measure’s items and responses in a visual text format.
Screen text devices include desktop and laptop computers, which
may include a touch screen; tablet or touch-screen notebook
computers; handheld/palm computers; and web-based systems.
Computer touch screen systems differ from traditional computer
keyboard and mouse systems by having a touch-sensitive
monitor screen that allows the patient to respond to questions by
the touch of a ﬁnger or stylus. Touch-screen applications may be
used with or without a keyboard or mouse; however, the stand-
alone desktop systems are limited in mobility.
Touch-screen tablet or laptop systems are usually full-
function computers that have few practical limits on the number
of ePRO questions, graphical displays (e.g., body diagrams,
visual analog scales), computational complexity, data storage, or
data transfer options. Because tablet or laptop computers offer
more screen space than other screen-based options, the question
and response text can be presented in larger font and displayed
on the same screen in practically all languages.
With handheld computer systems/devices, data are entered
via the touch sensitive screen using a special pen/stylus. Hand-
held computers offer the advantage of being lightweight and the
most portable of the screen text devices, but the drawback can be
limited screen space. This may require the respondent to scroll to
view the entire question and response set. It also limits the use of
larger, easier to read fonts. However, portability of the handheld
computer gives it the advantage of being potentially more useful
for real-time assessment of patient experience such as eDiaries
[3,38].
Web-based systems offer the advantage of capturing the PRO
data in the data ﬁle as the patient is responding to the question-
naire. The data does not need to be transferred to a central server,
which is the process required by the other screen-based systems
and has been known to present challenges to study subjects and
study site staff. In addition, web-based systems can accommodate
protocol and other changes during a study much more easily and
at much less cost than the other screen-based systems because the
changes only need to be made to the software residing on the
central server. Other screen-based systems require software
changes to be uploaded to each device, which can create signiﬁ-
cant logistical and technical challenges. Web-based ePRO
systems require access to a computer with internet service or a
device enabled with access to a wireless network. Depending
on the study protocol, web-based systems potentially offer the
respondent the convenience of completing the questionnaire in
their home. The touch-screen and mobility advantages may be
lost unless the computer has touch-screen and internet capabili-
ties; however, the latter is becoming increasingly available in
most countries.
Audiovisual computer-assisted self interviewing (A-CASI) is
an EDC hybrid device that combines screen text and voice/
auditory functionality into one platform. Respondents are pre-
sented with a questionnaire on a computer monitor, with or
without a touch screen, accompanied by an audible reading of the
questions and responses. Hybrid devices can offer the respondent
the choice of disabling the audio reading of the questionnaire and
responding to the visual presentation only, or vice versa,which can
be useful for assessing special populations (low literacy or visually
impaired) [39].
Voice/auditory devices provide the respondent with an audio
version of the questions and response choices. Speciﬁcally, IVR
systems are automated telephone-based systems that interact
with callers using a pre-recorded voice question and response
system. Some of the advantages of IVR are that no additional
hardware is required for the respondent other than a telephone,
little if any respondent training is necessary, data are stored
directly to the central database, and IVR systems can record
voice responses. The use of the recorded voice prompts has been
shown to reduce the literacy skill requirements of study partici-
pants [40,41]. IVR systems accept a combination of voice input
and touch-tone keypad selection to facilitate the completion of
questionnaires. IVR systems allow for respondents to call in or
for the system to call respondents; however, it is recommended
that researchers provide written complementary materials for
questions and response options at the start of the study, particu-
larly for lengthy questionnaires. The auditory presentation of
IVR systems departs from the visual medium in which most PRO
measures were developed, but it is very similar to telephone
interview-administered modes of data collection. Few studies
have directly compared IVR and paper-based versions of PRO
measures. Further research is needed to assess whether and under
what conditions (e.g., length of assessment or item, number of
options, respondent cognitive capacity) transfer from PRO
written modalities to IVR yields equivalent data.
The choice among the different ePRO platforms should con-
sider the type of PRO measure being adapted, the target popu-
lation, the complexity of data capture requirements or scoring
calculations, and the time frame required for patient reporting
(e.g., immediate vs. recall). For all the above ePRO applications
where the data are not stored immediately in a central database,
once the data are collected, they should be transferred as soon as
possible via internet, intranet, or server-based system to a cen-
tralized storage and processing facility.
Comparisons of Electronic and Paper Modes of PRO
Administration in the Literature
A number of studies have directly compared data obtained with
electronic and paper modes of PRO administration. Gwaltney
et al. [42] performed a meta-analysis that included 46 studies and
over 275 PRO measures to examine the relationship between
paper PROs and computer screen-based ePROs. The average
mean difference between the modes was very small (0.2% of the
scale range or 0.02 points on a 10-point scale) and the average
correlation between the paper and ePRO measures indicated
redundancy (0.90). The cross-mode correlation was often similar
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to the test–retest reliability of the paper measure, which indicates
equivalence of the measures. In such circumstances, administer-
ing the paper measure and then the ePRO is essentially the same
as administering the paper PRO measure twice.
Several different computer screen-based devices were used for
administering PROs in the reviewed literature; including com-
puter touch screen, handheld computers, web-based platforms,
as well as traditional computer monitor, keyboard, and mouse.
There was little evidence that the size of the computer screen,
respondent age, or amount of computer experience meaningfully
inﬂuenced the equivalence of the ePRO [42].
Studies in which IVR systems have been used to collect
patient-reported data have provided support for the reliability
and feasibility of the data collection mode [43,44]. Other studies
have compared traditionally clinician-administered/completed
clinical rating forms with IVR-administered patient-completed
versions [45–47]. Mundt et al. [46] compared an IVR-
administered version of the Montgomery-Asberg Depression
Rating Scale to clinician administration in a small sample
(n = 60) of patients. The ﬁndings provided initial evidence of the
equivalence of the administration modes based on the lack of
statistically signiﬁcant or clinically meaningful total score mean
difference. Rush et al. [47] compared three modes of administra-
tion (clinician rating, paper-based self report, and IVR) of the
Quick Inventory of Depressive Symptomatology (QIDS). They
found that in nonpsychotic patients with major depressive disor-
der, the IVR and self-report versions of the QIDS performed as
well as the clinician-rated version in terms of internal consistency
reliability and all three versions provided comparable mean total
scores. Agreement between the three self-report versions of the
QIDS regarding pre-deﬁned response to treatment (Yes/No) was
acceptable based on kappa coefﬁcients (0.72 to 0.74).
There are few publications comparing PRO measures origi-
nally developed for paper-and-pencil self-administration with an
IVR-adapted administration. Alemi et al. [48] compared IVR
administration of a follow-up questionnaire for recovering drug
addicts with a mailed, self-administered version. They found no
signiﬁcant differences between the responses collected via the
two modes but that the IVR mode had a higher response rate.
Agel et al. [49] compared the responses obtained on an IVR-
administered version of the Short Musculoskeletal Function
Assessment (SMFA) questionnaire to those obtained with a paper
self-administered version. Based on the crossover design, there
were no signiﬁcant differences between the means of the
responses on the versions of the questionnaire. Dunn et al. [50]
tested correspondence between the original paper version and an
IVR version of the Changes in Sexual Functioning Questionnaire
(CSFQ). The authors reported high Pearson product–moment
correlations between the versions for both the CSFQ total score
and the individual subscales scores.
The published literature addresses other types of comparisons
between ePROs and paper PROs, including time to completion,
satisfaction/ease of use, and missing data [51]. Although time to
completion was often used as a comparison measure between the
paper-based and the electronic adaptation of the PRO question-
naires, the ﬁndings are equivocal and the implications are
unclear. In some studies, respondents were faster on the elec-
tronic version than the paper version [29,52,53] and, in other
studies, respondents were faster on the paper version [54–56].
Results have indicated that less computer experience, older age,
poorer physical condition, and lower education were associated
with more time needed to complete the ePRO [29,56,57]. Other
than level of computer experience, these inﬂuences are not
unique to ePROs. Some studies found that although patients
took longer to complete the ePRO form, they reported that they
thought completion took less time for ePROs compared with the
paper version [58].
Other outcomes used to evaluate ePROs, such as satisfaction
and ease of use, were usually measured through the administra-
tion of follow-up questions after PRO completion. Typically,
respondents were asked about the ease of using the electronic
format, the adequacy of the instructions, ability to read the
screen, and the acceptability of the time taken to complete
the questionnaires. Respondents generally reported that they
preferred the ePRO over the paper PRO [29,52–56,59].
Quantity of missing data was another important comparison
between paper PRO and ePRO modes of administration
[29,53,60,61]. ePROs typically produce less missing data than
paper-based measures, but the amount of usable data from each
format should be compared. One potential problem regarding
missing data with handhelds is that the devices themselves can be
lost. To allow respondents the ability to opt out of answering
individual items, ePRO instruments should have “choose not to
respond” or “skip question” response options or some other
means of moving forward without answering. In addition, the
ability to review and change prior responses are a characteristic
of paper-based forms that can be implemented with all ePRO
devices.
Evidence Needed to Support
Measurement Equivalence
Deﬁnition of Measurement Equivalence
An ePRO measure that has been adapted from a paper-based
measure ought to produce data that are equivalent or superior
(e.g., higher reliability) to the data produced from the original
paper version. Measurement equivalence is a function of the
comparability of the psychometric properties of the data
obtained via the original and adapted administration mode. This
comparability is driven by the amount of modiﬁcation to the
content and format of the original paper PRO measure required
during the adaptation process. Hence, the amount of change
that occurs during migration to the electronic platform/device
will dictate the amount of evidence necessary to demonstrate
that the change did not introduce response bias and/or negatively
affect the measure’s psychometric properties. As noted in the
FDA draft guidance [18, lines 582–583], “The extent of addi-
tional validation recommended depends on the type of modiﬁ-
cation made.”
In Table 1, we provide a framework for assessing the magni-
tude of a particular change and match the degree of change with
a recommended strategy for assessing measurement equivalence.
The magnitude of a particular change is deﬁned with reference to
its potential effect on the content, meaning, or interpretation of
the measure’s items and/or scales. Note that the FDA draft PRO
guidance does not make the distinction between minor, moder-
ate, or substantial modiﬁcations. The draft guidance indicates
that additional validation is required when “an instrument is
altered in item content or format” [18, line 619]. Our goal is to
be more explicit about how much additional validation is needed
given the modiﬁcations to the paper version to convert it to an
ePRO mode of administration. Full psychometric validation for
every modiﬁcation is impractical and, furthermore, not necessary
based on current evidence.
1. A minor modiﬁcation is not expected to change the content
or meaning of the items and response scales. Simply placing
a scale from a paper-and-pencil format into a screen text
format without signiﬁcantly reducing font size, altering item
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content, recall period, or response options qualiﬁes as a
minor modiﬁcation. This includes an appreciation of the
fact that a one-item-per-screen electronic format differs
from the many-items-per-page paper format. The large lit-
erature on migrating from paper- to screen-based platforms
suggests that these common modiﬁcations will not have
a substantive effect on the performance of the measure [42].
However, it is still important to provide some evidence for
the equality of the ePRO measure to other modes of data
collection. In these cases, small-scale (5–10 patients) cogni-
tive interviewing [63] and usability testing (see below) can
establish that participants are responding to the assessment
items in the intended manner and that the ePRO software
works properly when used by the target population.
2. A moderate level of modiﬁcation may change the meaning
of the assessment items, but this change might be subtle.
Examples of changes to items that could fall in this category
include splitting a single item into multiple screens, signiﬁ-
cantly reducing the font size, and requiring the patient to
use a scroll bar to view all item text or responses. Another
example might include changing the order of item presen-
tation. When these types of modiﬁcations are made to a
PRO, it is advisable to formally establish the equivalence of
the electronic measure. Designs that can be used to establish
equivalence are discussed below. We include migrating from
paper PROs to IVRS in this category because 1) it remains
unclear whether there are reasons to be concerned about the
changes involved in moving from paper to IVRS (e.g., visual
to aural presentation); and 2) the available literature sup-
porting the equivalence between IVRS and paper is emerg-
ing and still not conclusive. In addition to assessing
measurement equivalence, usability testing should be con-
ducted in the target population.
3. Substantial modiﬁcations almost certainly will change the
content or meaning of the assessment. Examples of changes
that could fall in this category include removing items to
decrease the amount of time it takes to complete an assess-
ment or making dramatic changes to item text, such as
removing references to a recall period or scale anchors, to ﬁt
an item on a screen. In this case, equivalence of the assess-
ments may be irrelevant and the modiﬁed measure should
be treated as a new measure. Estimating the comparability
of the old and new versions of the measure may still be
valuable for some purposes such as bridging scores [64].
Little or none of the data on the reliability and validity of
the original measure will be informative in judging the
quality of the modiﬁed measure. Therefore, studies designed
to assess the psychometric characteristics of the new
measure are required along with large-scale usability testing
in the target population.
Levels of Evidence
Cognitive debrieﬁng. Cognitive debrieﬁng (a.k.a., cognitive
interviewing or cognitive testing) is becoming increasingly impor-
tant in the development and testing of many types of question-
naires [63]. Cognitive interviewing techniques are used to
explore the ways in which members of the target population
understand, mentally process, and respond to the items on a
questionnaire [65]. Although most often associated with ques-
tionnaire development, cognitive debrieﬁng is directly applicable
to the pretesting of alternative modes of administration for exist-
ing measures. Cognitive debrieﬁng consists of the use of both
verbal probing by the interviewer (e.g., “What does the response
‘some of the time’ mean to you?”) and think aloud in which the
interviewer asks the respondent to verbalize whatever comes to
mind as he or she answers the question [66].
In this context, cognitive debrieﬁng would be used to assess
whether the ePRO application changes the way respondents
interpret the questions, decide on an answer, and respond. In
addition, it can help to determine whether the instructions were
clear or if anything was confusing. The cognitive debrieﬁng
should be conducted with 5 to 10 patients [67], but more may be
necessary to adequately reﬂect the target study population. It is
important to fully document the process along with the qualita-
tive ﬁndings and any resulting changes.
Usability testing. Usability testing examines whether respon-
dents from the target population are able to use the software and
the device appropriately. This process includes formal documen-
tation of respondents’ ability to navigate the electronic platform,
follow instructions, and answer questions. The overall goal is to
demonstrate that respondents can complete the computerized
assessment as intended. The scale of the usability testing process
should be based on the complexity of the physical and cognitive
tasks required for the speciﬁc ePRO application. The character-
istics of the PRO measure (e.g., number and format of items,
types of response scales, number of response options) in combi-
nation with the characteristics of the ePRO device/platform (e.g.,
Table 1 PRO to ePRO measurement equivalence: instrument modiﬁcation and supporting evidence
Level of modiﬁcation Rationale Examples Level of evidence
Minor The modiﬁcation can be justiﬁed on the basis of
logic and/or existing literature. No change in
content or meaning.
1) Nonsubstantive changes in instructions (e.g.,
from circling the response to touching the
response on a screen).
2) Minor changes in format (e.g., one item per
screen rather than multiple items on a page).
Cognitive debrieﬁng
Usability testing
Moderate Based on the current empirical literature, the
modiﬁcation cannot be justiﬁed as minor. May
change content or meaning.
1) Changes in item wording or more signiﬁcant
changes in presentation that might alter
interpretability.
2) Change in mode of administration involving
different cognitive processes (e.g., paper
[visual] to IVR [aural]).
Equivalence testing
Usability testing
Substantial There is no existing empirical support for the
equivalence of the modiﬁcation and the
modiﬁcation clearly changes content or
meaning
1) Substantial changes in item response options
2) Substantial changes in item wording
Full psychometric testing
Usability testing
Adapted from Shields et al. [62].
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visual vs. aural, touch-tone vs. touch-screen, stylus vs. ﬁnger)
drives the number of subjects needed. Usability testing may
require a small number of subjects (5 to 10) for an ePRO device
that is simple to use or a larger sample (20 or more) for one that
is more physically and/or cognitively complex.
Usability testing as described above is not the same as another
process called user acceptance testing (UAT). The purpose of
UAT is to determine whether the software complies with the
written system speciﬁcation or user requirements document.
It is not intended solely to determine if respondents like or can
use the system. UAT is one aspect of an extensive system/
software validation process that is far beyond the scope of this
manuscript.
Equivalence testing. Equivalence testing is designed to evaluate
the comparability between PRO scores from an electronic mode
of administration and paper-and-pencil administration. The
intent is to ensure that PRO scores from the ePRO do not vary
signiﬁcantly from those scores from a paper questionnaire
(except for measurement error). There are several study designs
and statistical methods that can be used to assess the compara-
bility of measurement obtained on two (or more) different occa-
sions. First, we discuss study designs followed by statistical
methods for equivalence testing.
Study Designs for Testing Measurement Equivalence
When it is necessary to test the measurement equivalence of an
ePRO adaptation, as in the second level of modiﬁcation listed in
Table 1, there are two recommended study designs: 1) the ran-
domized parallel groups design; and 2) the randomized crossover
design. The study sample should be representative of the
intended patient group in which the ePRO will be used, particu-
larly with regard to age, gender, race/ethnicity, education, and
disease severity.
Randomized parallel groups design. In the randomized parallel
groups design, patients are randomly assigned to one of two
study arms. In this design, patients in one study arm would
complete the original paper version of the PRO measure and
patients in the other arm would complete the ePRO measure.
Comparisons of mean score differences can then be made
between groups. The random assignment of an adequate number
of patients to each of the two study arms is designed to yield
equivalence of the characteristics of the two groups. More elabo-
rate studies based on a parallel groups design could involve more
than two comparison groups (e.g., paper PRO vs. tablet ePRO
vs. IVRS ePRO) or could incorporate a repeat administration
(within mode) after a two-day to two-week interval. The latter
would provide directly comparable test–retest reliability for the
paper PRO and ePRO measures.
There are two possible approaches for testing of equivalence
in a parallel groups design: 1) set a mean difference “d” that
would be the minimum effect size that is indicative of a lack of
equivalence and calculate a sample size to detect the difference
“d” with sufﬁcient power; or 2) set a level of difference “d” that
is the maximum that would be tolerated for equivalence to be
accepted, express the hypothesis testing in terms of ruling out
differences smaller than “d,” and calculate a sample size that
would be required to rule out such a difference being present. The
ﬁrst approach would be erroneous [68,69]; it is inherent in the
logic of statistical inference that one draws a deﬁnitive conclu-
sion when a hypothesis is rejected, not when it fails to be rejected.
Blackwelder [70] provides an accessible summary of carrying out
equivalence testing procedures, and Atherton and Sloan [71]
provide convenient design algorithm macros. Compared to clas-
sical hypothesis testing, the equivalence approach will inﬂate the
sample size required to demonstrate equivalence by as much as
one-third greater [69]. To rule out differences between a paper-
based PRO and ePRO assessment of 0.3 standard deviations (a
small effect size), a two-sample t test based on 234 patients per
group would provide 80% power with a two-tailed alternative
and a 5% Type I error rate.
Randomized crossover design. The use of the crossover design in
ePRO equivalence studies would involve the random assignment
of respondents to complete either a paper PRO or ePRO measure
for the ﬁrst administration and then the other mode for the
second administration. Adequate time should be allowed
between administrations to minimize memory or testing effects
from the ﬁrst administration (referred to as a carryover effect),
but not so long that the underlying concept (e.g., pain, fatigue)
might actually change. Testing and order effects can weaken the
internal validity of this study design, but the within-patient
design provides greater statistical power and decreases sample
size requirements. Both testing and order effects should be
accounted for as described in most statistical textbooks on the
analysis of clinical trials. Detailed statistical methods and
example studies are described along with a set of computational
algorithms in Sloan, Novotny et al. [72] and Sloan and Dueck
[73].
By incorporating the reduced variance estimates that arise
from using patients as their own controls, the methods for deter-
mining sample size for crossover studies are a slight modiﬁcation
of those described for parallel groups designs above. A simple
method of estimating the sample size required for crossover
design comparisons of means from two different PRO adminis-
tration modes is to multiply the total sample size required for a
parallel groups design by a factor of (1 - r)/2 where r is an
estimate of the expected correlation between the two modes of
administration (or to be conservative, an estimate of the lower
bound). For example, as indicated above, a parallel groups
design using equivalence methodology with 234 patients per
group can exclude a difference between means of 0.3 standard
deviations (equivalent to a small effect size [74]). If we assume an
expected value of r = 0.9, then the required sample size is 468 *
0.05 = 23.4 (i.e., 24); if we assume an expected value of r = 0.7,
then the required sample size is 468 * 0.15 = 70.2 (i.e., 71). The
efﬁciency of the crossover design explains why it is the most
popular design as evidenced by the meta-analysis performed by
Gwaltney et al. [43]. Note that the calculated sample sizes denote
the number of completed pairs of assessments necessary for
the analysis and appropriate adjustments should be made for
noncompletions.
The above sample size calculations are all based upon designs
involving comparisons of mean scores. If the end point of interest
is the intraclass correlation coefﬁcient (ICC), the sample size
calculations differ somewhat. First, the sample size for this situ-
ation only applies to crossover designs because the ICC is not
relevant for parallel group designs. Second, the hypothesis to be
tested in this situation is whether the population ICC is sufﬁ-
ciently large to indicate that the scores for the paper PROs and
the ePROS are psychometrically equivalent. The test is based on
a standard normal test statistic (Z-score) and whether the one-
sided conﬁdence interval (lower bound) is above the speciﬁed
equivalence threshold (e.g., 0.70). For example, 43 patients with
complete paired observations would be required for a study to
have 80% power to declare that true population reliability is
above 0.70 with 95% conﬁdence if the underlying population
ICC is 0.85 using Walter’s methodology [75]. Alternative calcu-
424 Coons et al.
lations are possible based on the consistency form of ICC [76] or
the 2 sided width of the conﬁdence interval around the ICC [77].
Statistical Methods for Evaluating
Measurement Equivalence
The ICC and weighted kappa are useful statistics to measure
agreement and, in this case, to test measurement equivalence. Use
of Pearson’s or Spearman’s correlation coefﬁcients alone is not
recommended because they are not sensitive to systematic mean
differences between groups and, as a result, tends to overestimate
agreement. Methods developed by Bland and Altman [78]
combine simple graphical techniques with hypothesis testing for
measurement equivalence. Several examples of applications of
these measurement equivalence procedures have been published
[79–82]. In addition, comparison of mean scores and the evalu-
ation of differential item functioning (discussed brieﬂy below)
may be appropriate to assess measurement equivalence.
ICC. The ICC, which can assess both the covariance and degree
of agreement between score distributions, has been used most
frequently in previous studies that examined the equivalence of
paper PROs and ePROs [42]. The ICC provides a means to assess
the reliability of scores from an instrument given on multiple
occasions or across multiple raters [83]. The ICC takes into
account both relative position in the group of scores and the
amount of deviation above or below the group mean [84].
Kappa coefﬁcient. Rather than computing simple agreement,
which may be high due to chance alone, the kappa coefﬁcient
corrects for this by examining the proportion of responses in
agreement in relation to the proportion of responses that would
be expected by chance alone [85]. The traditional kappa compu-
tation only considers absolute agreement and does not credit
ratings that are close to one another but not in exact agreement.
However, an extension of this approach, called the weighted
kappa, considers such “partial” agreement [86]. Weighted kappa
and the ICC are similar and, in some cases, equivalent [87].
Hence, we recommend using ICC in most cases. Fleiss [88]
suggests that kappa coefﬁcients of less than 0.40 are poor, 0.40 to
0.59 are fair, 0.60 to 0.74 are good, and greater than 0.74 are
excellent. For ICC results, we recommend conforming to the
standards for acceptable levels of reliability, speciﬁcally at least
0.70 for group comparisons and 0.85 to 0.95 for applications at
the individual levels [89,90].
Comparison of mean scores. Comparing the mean scores
obtained on the two modes of administration from the same
person [52,91] or from two equivalent groups can be used to
assess measurement equivalence. This approach is most appro-
priate when the calculation of an ICC is not possible (i.e., in a
randomized parallel group design). The difference between
modes should not exceed what would be considered the mea-
sure’s minimally important difference (MID). For those measures
for which there is an established MID, the mean difference is
evaluated relative to that value. If an MID has not been docu-
mented in the literature, then an estimate of the MID is required.
A commonly used framework for expressing such estimates,
endorsed in the FDA draft guidance, is based on Cohen’s rules of
thumb for effect sizes [74]. A “small” effect size (difference of
between 0.20 SD and 0.49 SD) may be meaningful and represent
an MID [92–97]. Hence, mean differences between modes of
administration in this range warrant further consideration before
concluding equivalence. When assessing measurement equiva-
lence, the mean difference between modes should be interpreted
relative to an estimate of the mean difference within mode in
repeated administrations. In addition, the ICC for ePRO vs.
paper administration should be compared to the test–retest ICCs
within mode. As noted earlier, the ePRO application should not
be held to a higher standard than the original paper-based PRO
measure. Further, mode differences may be the result of the better
measurement properties of the ePRO device.
Differential item functioning. Another approach to assessing
mode equivalence is by using item response theory (IRT) or other
approaches to evaluate differential item functioning (DIF)
[98,99]. The probability of responding to each response category
for an item should be invariant to mode of administration, con-
ditional on the estimate of underlying score on the domain being
measured. For example, people who are estimated to have the
same level of physical functioning should have the same prob-
ability of answering “not limited at all” to a question about
running a mile whether they respond on a self-administered
paper questionnaire or over the internet. If the probabilities
differ, that is an indication of DIF and lack of mode equivalence.
A simple analog to the IRT approach to DIF is to condition on
the total domain score rather than the IRT estimated score [100].
Note that for DIF analyses, larger sample sizes (200 minimum;
500 preferred) are needed than the sample size needed for ICCs
or weighted kappas.
Other considerations. In addition, the variance and distribution
of scores and, when appropriate, the internal consistency reli-
ability, should also be compared. Cronbach’s alpha coefﬁcient
can be used to estimate the internal consistency reliabilities for
the different modes and the signiﬁcance of the difference in
reliability between the modes can be computed [101]. As with the
ICC, internal consistency reliability coefﬁcients should be at least
0.70 for group comparisons and 0.85 to 0.95 for applications at
the individual level [89,90]. While DIF can provide important
information about lack of equivalence at the item level, it is
important to evaluate measurement equivalence corresponding
to how the measure will be scored. A PRO measure may have a
total score and multiple subscale (domain) scores; therefore, the
total and subscale scores should be evaluated for measurement
equivalence. If item-level DIF is present but operates in different
directions, then it is possible to have measurement equivalence at
the scale score level.
Full Psychometric Evaluation
When substantial change has occurred in the PRO measure
migration process that has the potential to impact fundamental
psychometric properties of the measure, then the measure should
be evaluated as if it were a new measure. The topic of PRO
questionnaire development and testing is covered sufﬁciently
elsewhere [20,21,77,102] and is likely to require both qualitative
and quantitative components. At minimum, the researchers will
need to document the content validity (i.e., conceptual frame-
work in the terminology of the FDA draft guidance) of the new
PRO measure, and provide evidence supporting internal consis-
tency and test–retest reliability, and construct validity of the
measure [22,103]. The sponsor is advised to also consult the
draft FDA PRO guidance document for evidentiary requirements
for PRO measures that are intended to be used to support label-
ing claims [18].
Various study designs can be used to evaluate the measure-
ment properties of these new ePRO measures, although most
often PRO instruments are evaluated using stand-alone observa-
tional studies or within randomized clinical trials. Detailed expli-
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cation of the psychometric research methods and study designs
for psychometric evaluation studies is beyond the scope of this
report. However, the main difference between designs for equiva-
lence testing and psychometric validation is the need to assess
validity in the latter, which necessitates the inclusion of a variety
of measures extrinsic to the scale of interest. The interested
reader is directed to several publications on psychometric evalu-
ation of PRO measures [22,77,102,104].
Discussion and Conclusions
It is unreasonable to expect that each speciﬁc ePRO application
developed from a paper-based PRO measure should undergo full
psychometric testing, as if it were a new measure. The expense
associated with that process is high, with the potential for little (if
any) scientiﬁc gain. As long as only minor modiﬁcations were
made to the measure during the migration process, a substantial
body of existing evidence suggests that the psychometric proper-
ties of the original measure will still hold for the ePRO version;
hence, an evaluation limited to cognitive debrieﬁng and usability
testing only may be reasonable. Nevertheless, as with any instru-
ment, ongoing assessment of reliability and validity should con-
tinue regardless of the mode of administration. However, where
more substantive changes in the migration process has occurred,
conﬁrming that the adaptation to the ePRO format did not
introduce signiﬁcant response bias and that the two modes of
administration produce essentially equivalent results is necessary.
In those cases, there is a need for a practical approach to assess-
ing the measurement equivalence of the ePRO application to the
original paper-based measure. Although it is not typically
optimal for two administration modes to be used in the same
study, there are situations where it happens and may even be
advisable (e.g., in a study of a hard-to-reach population where
multiple modes improve the overall response rate [105]). In
addition, comparability with data from other trials in which the
original PRO measure was used is beneﬁcial.
This paper does not address the cross-cultural adaptation of
paper PRO measures from one language to ePRO applications
for use in other languages or cultures. When standard cross-
cultural translation and adaptation procedures [106–108] have
been used with the original PRO questionnaire and an acceptable
version has been produced, the adaptation of that translated
version to an ePRO platform should only require the level of
testing necessary based on the changes made in the migration
process. However, it must be recognized that a translation could
result in longer items or response labels. Hence, for small screen-
based ePRO devices, the ﬁt or placement of items or responses on
the screen may be more problematic than that of the original
language version. As recommended in all cases, the new ePRO
version of a cross-culturally adapted measure should at least
undergo usability testing and cognitive debrieﬁng in the target
population prior to its use in a clinical trial.
Although not within the scope of this paper, the migration of
a measure developed speciﬁcally for an EDC device to a paper-
based mode of administration may prove to be more problematic
than the other way around. The ease of incorporation of skip
patterns that are seamless to respondents in EDC is harder to
implement on paper questionnaires. Some respondents on the
paper form may respond to questions that should be skipped
resulting in uncertainty about which responses are reﬂecting the
respondent’s true response.
ePRO use in special populations (e.g., visually or cognitively
impaired, depressed, limited ﬁne motor skills) was not substan-
tively discussed here because most of the potential problems also
exist for paper-based questionnaires. There are issues that may
have particular salience with particular ePRO devices such as
font size on handheld computers and auditory volume for the
hearing impaired on IVR systems. Practical considerations
derived from usability testing and cognitive debrieﬁng can inform
the decision to use a particular ePRO platform based on the
target patient population [109].
We have provided a general framework for decisions regard-
ing the level of evidence needed to support modiﬁcations that are
made to PRO measures when they are migrated from paper to
ePRO devices. The key issues include 1) the determination of the
extent of modiﬁcation required to administer the PRO on the
ePRO device and 2) the selection and implementation of an
effective strategy for testing the measurement equivalence of the
two modes of administration. Not all contingencies could be
covered in the context of this paper, but we have attempted to
address the most common circumstances. The electronic admin-
istration of PRO measures offers many advantages over paper
administration. We hope that our recommendations provide a
path forward for researchers interested in migrating PRO mea-
sures to electronic platforms.
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